2024年4月17日_老虎社区_美港股上老虎 - 老虎社区

2024年4月17日礼来开盘大幅上涨

礼来首个小分子口服GLP-1药物3期临床研究成功有望颠覆减重药物格局

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":426203250442896,"tweetId":"426203250442896","gmtCreate":1745077389490,"gmtModify":1745077394048,"author":{"id":203325716325336,"idStr":"203325716325336","authorId":203325716325336,"authorIdStr":"203325716325336","name":"三袋地主","avatar":"https://static.tigerbbs.com/f11f1a2f0ac2e7f1a57af6fd73214b32","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":683,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://static.tigerbbs.com/768e2f9b2914d5ee78e0af1093be7cd6"}],"coverImages":[{"img":"https://static.tigerbbs.com/768e2f9b2914d5ee78e0af1093be7cd6"}],"html":"<html><head></head><body><p>2024年4月17日礼来开盘大幅上涨</p><t-t type=\"img\" src=\"https://static.tigerbbs.com/768e2f9b2914d5ee78e0af1093be7cd6\"></t-t></body></html>","htmlText":"<html><head></head><body><p>2024年4月17日礼来开盘大幅上涨</p><t-t type=\"img\" src=\"https://static.tigerbbs.com/768e2f9b2914d5ee78e0af1093be7cd6\"></t-t></body></html>","text":"2024年4月17日礼来开盘大幅上涨","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/426203250442896","repostId":2528080431,"repostType":2,"repost":{"id":"2528080431","kind":"news","pubTimestamp":1744956431,"share":"https://www.laohu8.com/m/news/2528080431?lang=&edition=full","pubTime":"2025-04-18 14:07","market":"hk","language":"zh","title":"礼来首个小分子口服GLP-1药物3期临床研究成功 有望颠覆减重药物格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2528080431","media":"证券日报","summary":"本报讯（记者李春莲见习记者梁傲男）4月17日，全球制药巨头礼来公司公布了3期临床研究ACHIEVE-1的积极顶线结果，该研究评估了Orforglipron与安慰剂相比，在患有2型糖尿病和仅通过饮食和运动控制不足的成人中的安全性和有效性。4月17日，礼来股价收涨超14%，创下自2023年8月份以来的最大单日涨幅。","content":"<html><body><div>\n<p><img border=\"0\" height=\"276\" src=\"https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=106.LLY&amp;imageType=k&amp;token=28dfeb41d35cc81d84b4664d7c23c49f&amp;at=1\" width=\"578\"/></p><p>　　本报讯 （记者李春莲见习记者梁傲男）4月17日，全球制药巨头<span><a href=\"https://laohu8.com/S/LLY\">礼来</a></span><span></span>公司公布了3期临床研究ACHIEVE-1的积极顶线结果，该研究评估了Orforglipron与安慰剂相比，在患有2型糖尿病和仅通过饮食和运动控制不足的成人中的安全性和有效性。</p><p>　　4月17日，<span href=\"http://quote.eastmoney.com/unify/r/106.LLY\" target=\"_blank\" web=\"1\">礼来</span>股价收涨超14%，创下自2023年8月份以来的最大单日涨幅。</p><p>　　在业内人士看来，GLP-1<span>减肥药</span><span></span>领域正在从注射剂型向便捷的口服形式转变，而<span href=\"http://quote.eastmoney.com/unify/r/106.LLY\" target=\"_blank\" web=\"1\">礼来</span>已经取得了早期领先优势，有望颠覆减重药物格局。</p><p>　　据礼来介绍，Orforglipron是首款无需饮食、饮水控制的口服小分子GLP-1受体激动剂。礼来方面表示，如果该药物未来获批，公司对其实现全球充足的供应充满信心。这将进一步实现礼来长期以来的使命——降低包括2型糖尿病在内的慢性病的影响。</p><p>　　“目前共有7项评估Orforglipron在糖尿病和肥胖人群中安全性和有效性的3期临床试验，ACHIEVE-1则是其中的首个研究。作为最新的肠促胰岛素类药物，我们很高兴看到它达到了我们对其安全性、耐受性、血糖控制和减重的各项预期，今年年底前我们将获得有关这一研究的更多数据。”礼来制药董事长兼首席执行官戴文睿表示。</p><p>　　研究显示，在ACHIEVE项目的第一项3期临床试验中，Orforglipron达到了主要终点，即在40周时，经Orforglipron治疗后糖化血红蛋白（A1C）的降幅显著优于安慰剂组，A1C自8.0%的基线平均降低1.3%至1.6%（使用有效性估计目标）。在关键次要终点，超过65%的患者接受最高剂量的Orforglipron后A1C值降至≤6.5%，低于美国糖尿病协会定义的糖尿病阈值。在另一个关键次要终点，接受Orforglipron的患者在最高剂量下平均减重7.3kg。鉴于患者在研究结束时尚未达到体重平台期，可能表明尚未实现完全减重。</p><p>　　礼来方面预计，将在今年年底前向全球监管机构提交Orforglipron用于体重管理的上市申请，预计于2026年提交其用于治疗2型糖尿病的上市申请。</p><p>（文章来源：<span>证券</span><span></span>日报）</p> </div></body></html>","source":"stock_eastmoney","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来首个小分子口服GLP-1药物3期临床研究成功 有望颠覆减重药物格局</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来首个小分子口服GLP-1药物3期临床研究成功 有望颠覆减重药物格局\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-18 14:07 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202504183381169424.html><strong>证券日报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>本报讯 （记者李春莲见习记者梁傲男）4月17日，全球制药巨头礼来公司公布了3期临床研究ACHIEVE-1的积极顶线结果，该研究评估了Orforglipron与安慰剂相比，在患有2型糖尿病和仅通过饮食和运动控制不足的成人中的安全性和有效性。　　4月17日，礼来股价收涨超14%，创下自2023年8月份以来的最大单日涨幅。　　在业内人士看来，GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变，而礼来...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202504183381169424.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LLY":"礼来","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4581":"高盛持仓","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","GLP":"全球合伙","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0385154629.USD":"贝莱德营养科学基金A2","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0079474960.USD":"联博美国增长基金A","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC"},"source_url":"http://finance.eastmoney.com/a/202504183381169424.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2528080431","content_text":"本报讯 （记者李春莲见习记者梁傲男）4月17日，全球制药巨头礼来公司公布了3期临床研究ACHIEVE-1的积极顶线结果，该研究评估了Orforglipron与安慰剂相比，在患有2型糖尿病和仅通过饮食和运动控制不足的成人中的安全性和有效性。　　4月17日，礼来股价收涨超14%，创下自2023年8月份以来的最大单日涨幅。　　在业内人士看来，GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变，而礼来已经取得了早期领先优势，有望颠覆减重药物格局。　　据礼来介绍，Orforglipron是首款无需饮食、饮水控制的口服小分子GLP-1受体激动剂。礼来方面表示，如果该药物未来获批，公司对其实现全球充足的供应充满信心。这将进一步实现礼来长期以来的使命——降低包括2型糖尿病在内的慢性病的影响。　　“目前共有7项评估Orforglipron在糖尿病和肥胖人群中安全性和有效性的3期临床试验，ACHIEVE-1则是其中的首个研究。作为最新的肠促胰岛素类药物，我们很高兴看到它达到了我们对其安全性、耐受性、血糖控制和减重的各项预期，今年年底前我们将获得有关这一研究的更多数据。”礼来制药董事长兼首席执行官戴文睿表示。　　研究显示，在ACHIEVE项目的第一项3期临床试验中，Orforglipron达到了主要终点，即在40周时，经Orforglipron治疗后糖化血红蛋白（A1C）的降幅显著优于安慰剂组，A1C自8.0%的基线平均降低1.3%至1.6%（使用有效性估计目标）。在关键次要终点，超过65%的患者接受最高剂量的Orforglipron后A1C值降至≤6.5%，低于美国糖尿病协会定义的糖尿病阈值。在另一个关键次要终点，接受Orforglipron的患者在最高剂量下平均减重7.3kg。鉴于患者在研究结束时尚未达到体重平台期，可能表明尚未实现完全减重。　　礼来方面预计，将在今年年底前向全球监管机构提交Orforglipron用于体重管理的上市申请，预计于2026年提交其用于治疗2型糖尿病的上市申请。（文章来源：证券日报）","news_type":1},"isVote":1,"tweetType":1,"viewCount":20,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":29,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/426203250442896"}